A powerful point-of-sale partnership that delivers on the promise of affordable insulin

GoodRx + Sanofi broaden access & affordability for people with diabetes.

 GoodRx announces new way for consumers to access Sanofi’s Lantus for $35 at over 70,000 pharmacies nationwide.

In October GoodRx announced it is working with Sanofi, a global leader in diabetes care, to offer a new way for people living with diabetes to access Lantus® (insulin glargine injection) 100 Units/mL in the U.S. for only $35. This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap OOP costs at $35 for all patients with commercial insurance, which goes into effect January 1, 2024.

Read the article about this unique partnership that leverages GoodRx’s reach and scale to broaden access and affordability for people living with diabetes. This means that all Americans with a valid prescription, regardless of insurance status, can use GoodRx at over 70,000 U.S. retail pharmacies to access a 30-day supply of Lantus for only $35. The price is available to cash-paying patients with a valid prescription.

Learn more about how GoodRx + Sanofi delivered on the promise of more affordable insulin.

READ THE ARTICLE

Download the App